140 related articles for article (PubMed ID: 7823396)
1. [Immunocytochemistry in the diagnosis of acute myeloid leukemia (M0)].
Saito M; Kuriyama K; Nagai K; Nonaka H; Hata T; Tusima H; Tabata S; Arimura K; Souda H; Nakamura H
Rinsho Ketsueki; 1994 Nov; 35(11):1297-304. PubMed ID: 7823396
[TBL] [Abstract][Full Text] [Related]
2. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-).
Seshi B; Kashyap A; Bennett JM
Br J Haematol; 1992 Jul; 81(3):374-7. PubMed ID: 1382546
[TBL] [Abstract][Full Text] [Related]
4. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0).
Kotylo PK; Seo IS; Smith FO; Heerema NA; Fineberg NS; Miller K; Greene ME; Chou P; Orazi A
Am J Clin Pathol; 2000 Feb; 113(2):193-200. PubMed ID: 10664621
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
7. Discordant expression of myeloid antigens and myeloperoxidase in a case of t(8;21) positive AML expressing CD7.
Hirai K; Torimoto Y; Moriichi K; Sato K; Ohnishi K; Taya N; Kohgo Y
Int J Hematol; 1999 Jul; 70(1):30-5. PubMed ID: 10446492
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody anti-MPO is useful in recognizing minimally differentiated acute myeloid leukaemia.
Praxedes MK; De Oliveira LZ; Pereira Wda V; Quintana IZ; Tabak DG; De Oliveira MS
Leuk Lymphoma; 1994 Jan; 12(3-4):233-9. PubMed ID: 8167554
[TBL] [Abstract][Full Text] [Related]
9. Intracellular markers in acute myeloid leukemia diagnosis.
Koníková E; Glasová M; Kusenda J; Babusíková O
Neoplasma; 1998; 45(5):282-91. PubMed ID: 9921916
[TBL] [Abstract][Full Text] [Related]
10. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
[TBL] [Abstract][Full Text] [Related]
11. A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: myeloperoxidase-positive and myeloid antigen-negative.
Specchia G; Mestice A; Clelia Storlazzi T; Anelli L; Pannunzio A; Grazia Roberti M; Rocchi M; Liso V
Leuk Res; 2001 Jun; 25(6):501-7. PubMed ID: 11337024
[TBL] [Abstract][Full Text] [Related]
12. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Evaluation and a proposal.
Kaleem Z; White G
Am J Clin Pathol; 2001 Jun; 115(6):876-84. PubMed ID: 11392885
[TBL] [Abstract][Full Text] [Related]
14. Detection of myeloperoxidase by flow cytometry in acute leukemia.
Nakase K; Sartor M; Bradstock
Cytometry; 1998 Aug; 34(4):198-202. PubMed ID: 9725460
[TBL] [Abstract][Full Text] [Related]
15. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
16. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes.
Venditti A; Del Poeta G; Buccisano F; Tamburini A; Cox MC; Stasi R; Bruno A; Aronica G; Maffei L; Suppo G; Simone MD; Forte L; Cordero V; Postorino M; Tufilli V; Isacchi G; Masi M; Papa G; Amadori S
Blood; 1997 Jan; 89(2):621-9. PubMed ID: 9002966
[TBL] [Abstract][Full Text] [Related]
17. Leukemias resembling acute promyelocytic leukemia, microgranular variant.
Nagendra S; Meyerson H; Skallerud G; Rosenthal N
Am J Clin Pathol; 2002 Apr; 117(4):651-7. PubMed ID: 11939742
[TBL] [Abstract][Full Text] [Related]
18. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
19. The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia.
Urbano-Ispizua A; Matutes E; Villamor N; Sierra J; Pujades A; Reverter JC; Feliu E; Cervantes F; Vives-Corrons JL; Montserrat E
Br J Haematol; 1992 Jun; 81(2):178-83. PubMed ID: 1322689
[TBL] [Abstract][Full Text] [Related]
20. Detection of myeloperoxidase gene expression in minimally differentiated acute myelogenous leukemia (AML-M0) using in situ hybridization.
Traweek ST; Liu J; Braziel RM; Johnson RM; Byrnes RK
Diagn Mol Pathol; 1995 Sep; 4(3):212-9. PubMed ID: 7493141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
